A 2024 comprehensive review (PMID 38176910) documents that capsaicin interferes with multiple hallmarks of cancer. In preclinical models, capsaicin induces apoptosis in cancer cells through both intrinsic (mitochondrial) and extrinsic pathways: it generates reactive oxygen species specifically within cancer cell mitochondria (exploiting cancer cells’ higher mitochondrial membrane potential), activates caspase-3 and caspase-9, enhances p53 expression, and downregulates Bcl-2 (an anti-apoptotic protein overexpressed in many cancers). Capsaicin also inhibits tumor angiogenesis by suppressing VEGF expression, reduces cancer cell migration and invasion by downregulating metalloproteinases, and suppresses NF-κB-driven inflammatory survival signaling. These effects have been documented in models of prostate, colon, lung, breast, and pancreatic cancers. A key question in translating preclinical data is dose: the concentrations used in many cell studies exceed what is achievable through diet alone. The post’s qualifier “in moderation” is apt, chronic very high chili intake has also been associated with gastric irritation and in some epidemiological studies with stomach cancer risk, suggesting a dose-dependent profile where moderate use is beneficial and excessive use potentially harmful.
Capsaicin activates TRPV1 receptors in brown adipose tissue, stimulating thermogenesis and increasing energy expenditure. Meta-analyses of capsaicin supplementation show modest but significant increases in metabolic rate (approximately 50 kcal/day) and fat oxidation. Capsaicin also reduces appetite acutely and lowers the glycemic response to high-carbohydrate meals in some trials, suggesting multiple complementary metabolic effects. These effects are modest individually but may accumulate with regular dietary use.
Capsaicin reduces oxidation of LDL cholesterol and stimulates endothelial nitric oxide production, improving vascular tone and blood flow. Observational epidemiology from a large Chinese cohort study found that regular chili consumption was associated with significantly lower cardiovascular mortality, an association that has not been experimentally confirmed in RCTs but aligns mechanistically with capsaicin’s endothelial and anti-inflammatory effects.
Topical capsaicin (0.025–0.075% cream) is an established treatment for neuropathic pain, postherpetic neuralgia, and osteoarthritis. It works by depleting substance P, the neuropeptide involved in transmitting pain signals, from peripheral nerve endings. Initial application causes burning; repeated use leads to receptor desensitization and sustained pain relief. This is the best-established clinical use of capsaicin, supported by multiple RCTs and regulatory approval.